Evaluation of dose‐dependent treatment effects after mid‐trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease-Reference-Cited by-同舟云学术

Evaluation of dose‐dependent treatment effects after mid‐trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease

Published:2022-01 Issue:1 Volume:14 Page:
ISSN:2352-8729
Container-title:Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
language:en
Short-container-title:Alz & Dem Diag Ass & Dis Mo

Author:

Wang Guoqiao¹^ORCID,Li Yan¹,Xiong Chengjie¹,McDade Eric¹,Clifford David B.¹,Mills Susan L.¹,Santacruz Anna M.¹,Aschenbrenner Andrew J.¹,Hassenstab Jason¹,Benzinger Tammie L.S.¹,Gordon Brian A.¹,Fagan Anne M.¹,Coalier Kelley A.¹,Libre‐Guerra Jorge J.¹,McCullough Austin¹,Joseph‐Mathurin Nelly¹,Chen Charles D.¹,Mummery Catherine²,Wendelberger Barbara A.³,Gauthier Serge⁴,Masellis Mario⁵,Holdridge Karen C.⁶,Yaari Roy⁶,Chatterjee Saptarshi⁶,Sims John⁶,Delmar Paul⁷,Kerchner Geoffrey A.⁷,Bittner Tobias⁷,Hofmann Carsten⁷,Bateman Randall J.¹,

Affiliation:

1. Washington University St Louis School of Medicine St. Louis Missouri USA

2. University College London London UK

3. Berry Consultants LLC Austin Texas USA

4. McGill University Centre for Studies on Aging in Montreal Montreal Quebec Canada

5. University of Toronto Sunnybrook Health Sciences Centre Toronto Ontario Canada

6. Eli Lilly and Company Indianapolis Indiana USA

7. F. Hoffmann‐La Roche, Ltd. Basel Switzerland

Publisher

Wiley

Subject

Psychiatry and Mental health,Neurology (clinical)